Analystreport

Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Citigroup Inc..

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com